Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia

Atherosclerosis Supplements

Volumn 15, Issue 2, 2014, Pages 33-45

  Cuchel, Marina ^a   Blom, Dirk J ^b,c   Averna, Maurizio R ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Apheresis; Homozygous familial hypercholesterolaemia; LDL cholesterol; Liver function tests; Lomitapide; Low fat diet; Microsomal transfer protein inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; AGOMELATINE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; BILIRUBIN; CHOLESTEROL; CLARITHROMYCIN; COLESEVELAM; EZETIMIBE; FERROUS SULFATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOMITAPIDE; LOPERAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN; BENZIMIDAZOLE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOATING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FAT CONTENT; FATTY LIVER; FEMALE; GENE DELETION; GENE MUTATION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; LIVER BIOPSY; LIVER FUNCTION TEST; LOW FAT DIET; MALE; MEDICAL HISTORY; NAUSEA; NUTRITIONAL COUNSELING; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; THORAX PAIN; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XANTHOMATOSIS; BLOOD; CASE REPORT; DRUG EFFECTS; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CHOLESTEROL, LDL; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908131271     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2014.07.005     Document Type: Article

References (17)

1. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46. European Society of Cardiology and European Atherosclerosis Society.
2. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
3. Bertolini S., Pisciotta L., Rabacchi C., Cefalu A.B., Noto D., Fasano T., et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 2013, 227:342-348.
4. Marais A.D., Blom D.J., Firth J.C. Statins in homozygous familial hypercholesterolemia. Current Atherosclerosis Reports 2002, 4:19-25.
5. Stein E.A., Honarpour N., Wasserman S.M., Xu F., Scott R., Raal F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013, 128:2113-2120.
6. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
7. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46. Phase 3 Ho FHLSi.
8. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Apheresis treatment does not affect the lipid-lowering efficacy of lomitapide, a microsomal triglyceride transfer protein inhibitor, in patients with homozygous familial hypercholesterolemia. Circulation 2012, 126:A17396.
9. Gagné C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475. Ezetimibe Study G.
10. Graesdal A., Bogsrud M.P., Holven K.B., Nenseter M.S., Narverud I., Langslet G., et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012, 6:331-339.
11. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490a. for the European Atherosclerosis Society Consensus Panel.
12. Bruckert E., Saheb S., Bonté J.R., Coudray-Omnés C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey. Atherosclerosis Supplements 2014, 15:46-51.
13. Aegerion Pharmaceuticals Inc Lojuxta summary of product characteristics 2013.
14. Tuteja S., Duffy D., Dunbar R.L., Movva R., Gadi R., Bloedon L.T., et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy 2014, 34:227-239.
15. Aegerion Pharmaceuticals Inc Juxtapid prescribing information 2013.
16. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
17. Kroon A.A., van't Hof M.A., Demacker P.N., Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000, 152:519-526.